Biohaven (NYSE:BHVN) Stock Price Down 6.9% – What’s Next?

Posted by Brenda Bartman on Oct 8th, 2026

Biohaven Ltd. (NYSE:BHVN – Get Free Report) shares were down 6.9% during mid-day trading on Tuesday. The stock traded as low as $12.09 and last traded at $12.0750. Approximately 844,959 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 2,676,781 shares. The stock had previously closed at $12.97.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BHVN shares. Morgan Stanley increased their price target on shares of Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research report on Thursday. Wall Street Zen upgraded Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Citigroup reaffirmed a “buy” rating on shares of Biohaven in a research note on Friday, September 18th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Biohaven in a report on Friday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Biohaven has an average rating of “Moderate Buy” and an average price target of $18.69.

View Our Latest Analysis on BHVN

Biohaven Trading Up 1.0%

The firm has a 50-day moving average price of $14.03 and a 200-day moving average price of $12.46. The stock has a market capitalization of $1.81 billion, a PE ratio of -2.56 and a beta of 1.35. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). As a group, equities analysts forecast that Biohaven Ltd. will post -3.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Biohaven

Large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its position in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after buying an additional 16,127,247 shares during the period. BlackRock Inc. purchased a new position in Biohaven during the 2nd quarter valued at about $196,574,000. Jupiter Topco LLC purchased a new position in shares of Biohaven during the second quarter valued at approximately $127,852,000. Stempoint Capital LP bought a new position in shares of Biohaven during the first quarter valued at approximately $13,489,000. Finally, Bank of America Corp DE purchased a new stake in Biohaven in the second quarter worth $21,990,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases.

Biohaven’s pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways.